4-(4,5,6,7-Tetrahydrothieno[2,3-c]pyridin-4-yl)benzene-1,2-diol | 79599-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 4-(4,5,6,7-Tetrahydrothieno[2,3-c]pyridin-4-yl)benzene-1,2-diol
• CAS: 79599-96-5
• 化学式: C₁₃H₁₃NO₂S
• 分子量: 247.31
• InChiKey: QDKUSZZMIFQVPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  80.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• 3,4-Dihydroxyphenyltetrahydrothienopyridines
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0040955A2

  公开（公告）日：1981-12-02

  3,4-Dihydroxyphenyltetrahydrothieno[2,3-c] or [3,2-c] pyridines are prepared by cyclization of a N-thienylmethyl-2-(3',4'-dimethoxyphenyl]-ethanolamine. These compounds have renal vasodilating activity. A species is 4-(3,4-dihydroxyphenyl]-1,2,3,4-tetrahydrothieno[2,3-c]-pyridine and its pharmaceutically acceptable acid addition salts or esters.

  3,4-二羟基苯基四氢噻吩并[2,3-c]或[3,2-c]吡啶是通过环化 N-噻吩基甲基-2-(3',4'-二甲氧基苯基]-乙醇胺制备的。这些化合物具有肾血管扩张活性。其中一种是 4-(3,4-二羟基苯基)-1,2,3,4-四氢噻吩并[2,3-c]吡啶及其药学上可接受的酸加成盐或酯。
• Dual function drugs and uses thereof
  申请人：Altar A. Charles

  公开号：US20070142399A1

  公开（公告）日：2007-06-21

  Dual action compounds are provided that are inhibitors of catechol-omethyltransferase (COMT) enzyme and are also partial agonists or antagonists of the D2 receptor, or agonists of the D1 receptor, or interact in these ways with both D1 and D2 receptors. Use of the compounds for treating neuropsychiatric disorders, particularly schizophrenia and mild cognitive impairment, is also described.
• DNA CYTOSINE DEAMINASE INHIBITORS
  申请人：Harris Reuben S.

  公开号：US20110218158A1

  公开（公告）日：2011-09-08

  Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.
• US4282227A
  申请人：——

  公开号：US4282227A

  公开（公告）日：1981-08-04
• [EN] DNA CYTOSINE DEAMINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA CYTOSINE DÉSAMINASE D'UN ADN
  申请人：UNIV MINNESOTA

  公开号：WO2010033986A2

  公开（公告）日：2010-03-25

  Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.